http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15311748

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial
endingPage 380
issn 1042-8194
1029-2403
issueIdentifier 2
pageRange 374-380
publicationName Leukemia & Lymphoma
startingPage 374
bibliographicCitation Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2007 Feb;48(2):374–80. doi: 10.1080/10428190601060496. PMID: 17325899.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9d73696c992360729db9fee6fd7bd792
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d333a1b098dbe1bde8d2a357341d2af
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1d4ad3c048d14ba9a20b96ee6ecfe85f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_111b6374e4cb1dabc55c927101443e35
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_be99e25da73696f3c76a8ba41950fad8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a03bc69f5cee18d0a36996459776aaee
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c85d04a19329b30415045edbc816489b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2b89893f649d54692086dc1d5a39ea17
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a75cb4ed3a4796faf859c01c209fe12c
date 200701
identifier https://doi.org/10.1080/10428190601060496
https://pubmed.ncbi.nlm.nih.gov/17325899
isPartOf https://portal.issn.org/resource/ISSN/1042-8194
https://portal.issn.org/resource/ISSN/1029-2403
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2306
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma
discusses http://id.nlm.nih.gov/mesh/M0005564
http://id.nlm.nih.gov/mesh/M0011785
http://id.nlm.nih.gov/mesh/M0004505
http://id.nlm.nih.gov/mesh/M0013662
http://id.nlm.nih.gov/mesh/M0229455
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D008224Q000188
http://id.nlm.nih.gov/mesh/D016879
http://id.nlm.nih.gov/mesh/D016393Q000188
http://id.nlm.nih.gov/mesh/D016403Q000188
http://id.nlm.nih.gov/mesh/D009364Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D008224Q000473
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D003561Q000008
http://id.nlm.nih.gov/mesh/D000971Q000493
http://id.nlm.nih.gov/mesh/D016393Q000473
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D007546Q000008
http://id.nlm.nih.gov/mesh/D016403Q000473
http://id.nlm.nih.gov/mesh/D008775Q000008
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D016403Q000378
http://id.nlm.nih.gov/mesh/D016393Q000378
http://id.nlm.nih.gov/mesh/D012074
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D009364Q000378
http://id.nlm.nih.gov/mesh/D002945Q000008
http://id.nlm.nih.gov/mesh/D011446
http://id.nlm.nih.gov/mesh/D008224Q000378
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5702198
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134019
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36462
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6741
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6253
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7078

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID134409758
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135867281
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128906544
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129367670

Total number of triples: 73.